TRIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Trinity Biotech PLC is not a strong buy at this moment for a beginner investor with a long-term strategy. The technical indicators are bearish, the financial performance shows declining net income and EPS, and the stock faces potential delisting risks. While the company has secured a $25 million equity purchase agreement, this is not enough to outweigh the negative trends and risks in the short term.
The stock is showing bearish technical indicators. The MACD is negative and expanding downward, RSI is neutral at 38.01, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The pre-market price is down 2.72%, and the stock is trading below the key pivot level of 0.736, with support at 0.643 and resistance at 0.83.
The company has secured a $25 million standby equity purchase agreement with Yorkville Advisors Global to support commercialization and R&D initiatives.
The company received a notice indicating it no longer meets Nasdaq's minimum public float requirement, risking delisting. Additionally, the financial performance shows declining net income (-29.19% YoY) and EPS (-81.82% YoY).
In Q3 2024, revenue increased by 3.24% YoY to $15.15 million, but net income dropped by 29.19% YoY to -$4.76 million, and EPS fell by 81.82% YoY to -0.04. Gross margin improved to 35.44%, up 21.54% YoY.
No data available for trend analysis or analyst ratings.
